Objectives-(I) To assess if patients with various forms of Raynaud's phenomenon (RP) have abnormal plasma fibrinolysis that may contribute to diminished digital blood flow; (2) to assess whether patients with RP with evidence of endothelial damage have abnormal plasma fibrinolysis; (3) to determine the clinical relevance of abnormalities, if any, in plasma fibrinolysis in patients with RP. Methods-One hundred and sixty eight patients with significant RP were studied-46 had primary Raynaud's disease (RD), 32 had suspected Raynaud's syndrome secondary to an undifferentiated connective tissue disorder (undifferentiated CTD), 25 had Raynaud's syndrome associated with atherosclerosis (athero RS), and 65 had an underlying connective tissue disease (CTD RS). All attended in the morning after a low fat light breakfast. After a clinical history was obtained, venous blood samples were collected without stasis for assays of plasma fibrinolysis and factor VIII von Willebrand factor antigen (fVIII vWF Ag). Results were compared with those obtained from normal subjects matched for sex and age. As patients with athero RS were significantly older than the other patients with Raynaud's phenomenon, two groups of control subjects were recruited-namely, 'old' and 'young' control subjects. Results-Patients with CTD RS and athero RS had higher concentrations of fVIII vWF Ag (CTD RS median 174-5 range (45-370)% v 100 (38-202)%, p<0*001;athero RS 182-5 (100-240)% v 100 (50-158)%, p<0-001). Both had raised fibrinogen (CTD RS 3 25 (1.9-6.8) g/l v 2*4 (1.2-4.2) g/l, p<0-001;athero RS 3.4 (2.2-6.2) g/l v 2*5 (1.8-3.9) g/l, p<0-001) and both had diminished fibrinolysis with reduced plasminogen activator activity (CTD RS 79*5 (31-72) mm2 v 92 mm2, p<0*04;athero RS 73 (45-125) mm2 v 98 (41-197) nun2 p<0-03). Patients with CTD RS also had raised plasminogen activity (3 3 (2-3-5-8) cU/ml v 2-9 (1-5-5-4) cU/ml, p<OOOl). On the contrary, patients with primary RD and undifferentiated CTD had normal fibrinogen and plasma fibrinolysis. Within each patient group, no significant differences in any of the measured variables were found between those who had RP all year and those who had RP in the winter only, those with RP of the hands only and of hands and feet, or those with and without digital ulcers. Conclusion-Dimiinished plasma fibrinolysis is found in patients likely to have endothelial damage (CTD RS and athero RS). These changes are probably a consequence rather than a cause of the disease.
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(Ann Rheum Dis 1993; 52: 443-448) Raynaud 's phenomenon (RP) was first defined by Maurice Raynaud in 1862 as episodic digital ischaemia provoked by cold and emotion.' It is a common condition affecting 50/6-10% of the population and is nine times more common in women than in men. Although RP may be benign when it is not associated with an underlying condition (primary Raynaud two week period. An attack was defined as white discoloration of one or more fingers, with or without paraesthesia, precipitated by cold, emotion, or a sudden drop in the surrounding temperature. The duration of the attack was also measured (in minutes) and was defined as the time elapsing between the start of an attack to the disappearance of blanching in the finger(s). The total number and duration of all attacks of Raynaud's phenomenon that occurred during the two week period were calculated.
ROUTINE BLOOD TEST
Routine blood haematology, biochemistry (including renal function), and immunology were carried out on all patients as part of screening for CTD.
ASSAYS OF PLASMA FIBRINOLYSIS AND FACTOR VIII VON WILLEBRAND FACTOR ANTIGEN
All subjects attended between 0900 and 1000 hours in the morning after a standard low fat light breakfast that comprised one slice of toast without butter and a glass of orange juice.
Patients were asked to refrain from cigarette smoking from the previous evening. All rested for at least 30 minutes before venepuncture. Blood samples were obtained without stasis with a gauge 19 butterfly at least 30 seconds after release of the tourniquet. The following assays were performed: Factors involved in thefibrinolytic pathway Fibrinogen, a substrate for fibrin that is involved in clot formation, was measured with the Automated Coagulation Laboratory nephelometric centrifugal analyser (Instrumentation Laboratory) by the method of Clauss.'2 Fibrinopeptide A, a degradation product of fibrinogen by thrombin, was measured with a competitive two step enzyme linked immunosorbent assay (Boehringer Mannheim). Plasminogen, the precursor of plasmin that lyses fibrin, was determined with a chromogenic substrate assay (Instrumentation Laboratory). This assay is not affected by raised plasma concentrations of fibrin degradation products and fibrinogen. Plasminogen activator activity was determined by fibrin plate lysis area. ' young control subjects (fig 1) . The cause of reduc'ed fibrinolysis in our prevented by the fibrinolytic system, which patients with athero RS and CTD RS is likely is also responsible for the removal of to be related to endothelial damage secondary inappropriately formed fibrin. Under such a to the underlying condition rather' than as a system the insoluble fibrin is degraded into the direct consequence of vasospasm. Both groups soluble fibrin degradation products by the of patients were shown to have raised action of the protease plasmin. Plasmin is concentration of fVIII vWF Ag, an endothelial produced, when required, by cleavage of its product that is released after damage to blood inactive precursor plasminogen and the rate of vessels. Patients with primary RD and this reaction is determined by the relative undifferentiated CTD had normal plasma proportions of activators and inhibitors of fVIII vWF Ag and fibrinolytic activity. That fibrinolysis. Diminished plasma fibrinolysis abnormal fibrinolysis is not directly related to impedes blood flow and has been shown to be vasospasm is further supported by the finding a major mechanism of thrombotic vascular that plasma fibrinolysis does not correlate with disease.'8 A defective fibrinolytic system may severity of symptoms. also be of aetiological importance in patients
In conclusion, diminished plasma fibrinowith RP.7-`0 Treatment of RP with fibrinolytic lysis is found in patients with secondary RS agents has been tried and was suggested to be (athero RS and CTD RS). This may be of value.1921 secondary to endothelial damage. These To our knowledge, this is the largest study changes are probably related to the underlying of plasma fibrinolysis in RP and hopefully condition rather than vasospasm as shown by resolves some of the published conflicts. their lack of correlation with frequency and Firstly, we have confirmed previous studies duration of vasospasm 
